Patients with colorectal cancer (CRC) enrolled in the US military's universal health care system experienced improved survival compared with patients in the general population, according to the results from a study, ‘Comparison of Survival among Colon Cancer Patients in the U.S. Military Health System and Patients in the Surveillance, Epidemiology, and End Results (SEER) Program’, published in Cancer Epidemiology, Biomarkers & Prevention.
"Colorectal cancer has the third highest death rate out of all cancers in the US. Therefore, it is highly important to improve survival of patients with colon cancer," said study author, Dr Craig D Shriver, a retired US Army colonel and professor and director of the Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences in Bethesda, Maryland.
Previous research has shown that patients without health insurance or with Medicaid (the US federal and state insurance program for low-income individuals) experience poorer survival from CRC than patients with private insurance. Little research has examined outcomes from the US Military Health System (MHS), which provides universal health care for active-duty service members, retirees, National Guard members, and their family members.
To compare survival between patients with CRC in the Military Health System and those in the general population, the researchers evaluated data from the Department of Defense's Automated Central Tumor Registry (ACTUR), matching 11,907 ACTUR patients to 23,814 patients in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. All patients were diagnosed with CRC between January 1987 and December 2013.
After a median follow-up time of 56 months for ACTUR patients and 49 months for SEER patients, the researchers found that the ACTUR patients with CRC had an 18 percent lower risk of death compared with the SEER patients. The lower risk of death was consistent across age groups, gender, race and year of diagnosis.
The survival benefit tended to be greater for Black patients, who typically have poorer CRC survival rates than white Americans. Black patients in the ACTUR database were 26 percent less likely to die of CRC than those in the SEER database. Among white patients, the survival benefit for ACTUR patients was the same as in the overall study population; they were 18 percent less likely than the SEER patients to die of CRC. While this study did not aim to compare survival between racial groups within ACTUR, previous research found that in the Military Health System, older Blacks and whites with CRC had similar overall survival.
Shriver explained that access to health care has been implicated as one factor in the disparities in cancer survival between Black and white Americans; therefore, the availability of universal health care through the military health system had a larger positive effect on the Black study population. "The survival benefit of Blacks in our study suggests that a universal health care system may be helpful to reduce racial disparity," Shriver said, adding that previous studies on lung cancer and glioma in the MHS showed similar success in reducing disparities.
The researchers also compared tumour stage at diagnosis, hoping to ascertain whether universal health care coverage resulted in earlier diagnosis. Colorectal cancer detected at early stages is more likely to be treated successfully.
The study showed that ACTUR patients were more likely than SEER patients to be diagnosed with stage 1 CRC (22.67 percent compared with 18.64 percent). ACTUR patients were less likely than the patients in the SEER database to be diagnosed with stage 4 CRC (18.74 percent compared with 21.63 percent).
"The Military Health System provides medical care with minimal or usually no financial barriers. Thus, our findings provide solid evidence of the benefits of access to universal health care," Shriver said. "What's more, when medical care is universally provided to all patients, racial disparity in colon cancer outcomes can be reduced."
Shriver noted that a limitation of the study is that the cancer registry data did not allow for a full comparison of all factors that could have affected survival among CRC patients. For example, the researchers could not compare treatment regimens, comorbidities or quality of care.